Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | huCART19-IL18-CD428z cells |
| Synonyms | |
| Therapy Description |
Limited information is currently available on huCART19-IL18-CD428z cells, putative autologous T-cells engineered to express two vectors, one targeting CD19-positive B-cells and the other targeting HIV (Nov 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| huCART19-IL18-CD428z cells | huCART19 IL18 CD428z cells|huCART19-IL18-CD428z T-cells | Limited information is currently available on huCART19-IL18-CD428z cells, putative autologous T-cells engineered to express two vectors, one targeting CD19-positive B-cells and the other targeting HIV (Nov 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07891468 | Phase I | huCART19-IL18-CD428z cells | huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers | Not yet recruiting | USA | 0 |